Key result
Novel oral anticoagulants for atrial fibrillation require further head-to-head and indirect comparisons to establish their relative clinical utility.
Key points are not available for this paper at this time.
Existing data insufficient to rank NOACs in AF; leaves open optimal agent selection pending head-to-head trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marx et al. (2012) studied this question. Novel oral anticoagulants for atrial fibrillation require further head-to-head and indirect comparisons to establish their relative clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: